Monte Rosa Therapeutics (GLUE) EBITDA (2020 - 2026)
Monte Rosa Therapeutics (GLUE) EBITDA from Mar 31, 2020 to Mar 31, 2026. The TTM Monte Rosa Therapeutics (GLUE) EBITDA is -$131M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Monte Rosa Therapeutics (GLUE) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 3 Years TTM | +3.46% |
| 5 Years TTM | +30.64% |
| All Time TTM | +30.65% |
Annual EBITDA change of Monte Rosa Therapeutics (GLUE)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$48M | +4.69% |
| 2025 | -$46M | -37.18% |
| 2024 | -$73M | -46.76% |
| 2023 | -$137M | +26.19% |
| 2022 | -$109M | +53.55% |
| 2021 | -$71M | +157.55% |
| 2020 | -$27M | N/A |
Comparison Monte Rosa Therapeutics (GLUE) five years EBITDA CAGR with competitors
Monte Rosa Therapeutics (GLUE) five years EBITDA CAGR is 30.64%.